- Premature ejaculation therapeutic market to see rapid growth over next 6 years
- Future market landscape set to change with new PE treatment launches
- Behavioural therapy used as an alternative to premature ejaculation medication
LONDON--(BUSINESS WIRE)-- In 2010 the premature ejaculation treatment market was estimated to be worth $684 million, according to a new research report available on companiesandmarkets.com. It is expected to increase in value by around 10.3% p/a to 2017, reaching $1.3 billion, on account of the anticipated US and European approval of Priligy (dapoxetine).
Premature Ejaculation (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
The premature ejaculation medication market represents a distinct unmet treatment need, as there are very few therapies in development, and those that are in use tend to be off-label (i.e., prescribed for an unapproved indication), such as SSRIs.
Forthcoming PE drugs include Priligy and topically applied PSD502/TEMPE. The market for PE therapeutics is highly competitive, as only Priligy is approved for treatment (and not in all countries).
Off-label drugs administered for the treatment of premature ejaculation include Prozac (fluoxetine), Zoloft (sertraline) and Paxil (paroxetine).
At present, physicians’ preferred treatment for premature ejaculation is a behavioural method termed ‘stop and squeeze’, which yields satisfactory results and has no side effects.
It is estimated that the premature ejaculation market was valued at US$684 million in 2010, with the sector forecast to expand at 10.3% compound annual growth rate to 2017. By the end of 2017, the premature ejaculation market is forecast to be valued at US$1.3 billion. The expected approval of the branded drug Priligy (dapoxetine) and the prevalence of PE in the male population is expected to drive this growth.
The 67 page premature ejaculation market report, published in July 2011, includes historical and forecast data between 2005-2017. It provides the reader with an overview of the premature ejaculation therapeutic market, including profiles of key companies such as Shionogi & Co, Vectura Group plc, GlaxoSmithKline and Dong-A Pharmaceutical Co., Ltd.
Subjects examined in detail include competitor analysis, product pipelines, trials by region and by product type, mergers/acquisitions and licensing, amongst many others. Geographies analysed within the premature ejaculation treatment forecast research report include France, Germany, Italy, Spain, Japan, UK and US.
Report Details:
CONTACT:
Companiesandmarkets.com
Mike King
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600
KEYWORDS: United Kingdom Europe
INDUSTRY KEYWORDS: Health Pharmaceutical Other Health
MEDIA:
| Logo |